Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study
Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Y. Choi, Jan H.M. Schellens, Jean‐Charles Soria, Patrick Y. Wen, C. C. Zielinski, Maria E. Cabanillas, Aislyn Boran, Palanichamy Ilankumaran, P. Burgess, T. Romero Salas, Bhumsuk Keam
Topics & Concepts
TrametinibDabrafenibMedicineAnaplastic thyroid cancerInternal medicineCohortOncologyProgression-free survivalClinical endpointPhases of clinical researchMEK inhibitorCancerThyroid cancerSurgeryClinical trialChemotherapyVemurafenibMAPK/ERK pathwayMetastatic melanomaCell biologyKinaseBiologyThyroid Cancer Diagnosis and TreatmentCancer, Lipids, and MetabolismLung Cancer Treatments and Mutations